Alipay+ partners LankaPay to enhance digital travel experience to and from Sri Lanka
More than 400,000 merchants in Sri Lanka will be able to accept cross-border digital payments from some of Asia’s most...
Alex
Alex is a writer and digital content enthusiast who enjoys covering technology, current trends, useful tips, and topics that matter to everyday readers. With a focus on clear, informative, and easy-to-understand content, Alex aims to provide readers with practical insights and interesting perspectives across a wide range of subjects.
SkyDrive Selected for Innovation Grant Worth up to 12.4 Billion Yen by Japanese Government
TOYOTA, Japan--(BUSINESS WIRE)--#FlyingCars--SkyDrive Inc. (“SkyDriveâ€), a leading Japanese eVTOL aircraft (*1) manufacturer based in Japan, is pleased to announce that...
Fearless, Solid and Reliable, DONGFENG KC Ushers a New Journey in the World
WUHAN, China--(BUSINESS WIRE)--Customer-oriented, in response to the dominance of road transport in many regions around the world, Dongfeng Commercial Vehicles...
HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma
HighField CEO Yuhong Xu and CBO Donald Wyatt are attending BIO-Europe, November 6 – 8, 2023 to discuss these significant...
Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
First market approval for Genexine discovered and developed therapeutic drug, Efesa (Efepoetin alfa), a long-acting erythropoietin (EPO) for the treatment...
National Football League Teams Up with SES for Game Content Distribution
In a renewed partnership, SES’s hybrid distribution network to enable the NFL to reach over 35 partners in Europe, Asia...
Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger
On October 23rd, at the EGM of shareholders, the merger agreement between Celltrion, Inc. & Celltrion Healthcare Co., Ltd. was...
Nidec Announces Financial Results for Fiscal Second Quarter and Six Months Ended September 30, 2023
KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO:6594) (OTC US:NJDCY) today announced its consolidated financial results under the International Financial Reporting Standards (“IFRSâ€)...
Nidec Announces Differences between Projected and Actual Financial Results for First-Half FY2023
KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (the “Companyâ€) today announced differences between its financial forecast for the...
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
Approval based on DESTINY-Lung02 trial results where Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a confirmed objective response rate of 49.0%...
Bias in AI Computer Vision Systems Dramatically Reduced with Synthetic Data ‘Digital Humans’
Mindtech’s Digital DNA technology creates a diverse range of Digital Humans that allow for statistically fair representation of the eight...
APO’s Newest Member Turkiye Hosts 64th Workshop Meeting of Heads of National Productivity Organizations
ANKARA, Turkiye--(BUSINESS WIRE)--#APO--Turkiye, the Asian Productivity Organization’s (APO’s) newest member, generously hosted the 64th Workshop Meeting (WSM) of Heads of...
Covation Holdings Continues Expansion in Asia Pacific With New Regional Corporate Headquarters
HONG KONG--(BUSINESS WIRE)--Covation Holdings Limited, the global manufacturer of multiple wheeled goods brands, today announced the addition of a new...
Berkshire Hathaway Specialty Insurance Names Sami Jaghbir as Underwriting Manager in Queensland
BRISBANE, Australia & BOSTON--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced that it has appointed Sami Jaghbir as Underwriting Manager,...
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy –...
